Christopher Jahraus, Paul Wallner, Dwight Heron, William Crook, Steven Finkelstein, Alexander Harris, Larry Kestin, Evan Landau, Douglas Rivera, Tarita Thomas, and Bridget Koontz
ACROPath Oligometastases: The American College of Radiation Oncology Clinical Pathway is first-of-its-kind guidance on how to approach patients with oligometastatic disease using radiotherapy. It offers both site-of-metastasis guidance as well as guidance on treatment based on the origin of the metastases. Additional works on other sites of disease are forthcoming and will similarly offer ACRO members timely, up-to-the-minute understandings of optimal approaches to treatment.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Miami-Dade County Medical Association and the American College of Radiation Oncology. The Miami-Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians.
The Miami-Dade County Medical Association designates this activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
None of the planners or faculty of this activity had any financial relationships to disclose except for Christopher Jahraus who disclosed he’s a consultant for RADformation, has other financial/material support from Klarity (Expert Witness), is a stock owner/investor in the privately held company Fuse Oncology, and is an advisory board member for Elekta. Paul Wallner disclosed he is an employee/owner of Genesiscare USA, a consultant for Health Management Associates, and an Advisory Board Member/has other financial/material support from Nanocan Therapeutics, Inc. Steven Finkelstein disclosed he’s on the speaker's bureau for Myriad JJ, is an advisory board member for Lantheas, Blue Earth, Bayer, Novartis, Myriad, & JJ. Bridget Koontz disclosed grant/research support with NCI (U10CA180868), is a stock owner/investor, for the privately held company Rythera Therapeutics, is an advisory board member with FUSE Oncology, Novartis, Myriad Genetics (which has ended). All of the financial relationships identified for these planners and faculty have been mitigated.
Jared Pasetsky, Dwight Heron, Paul Wallner, Jayden Gracie, Christopher Jahraus, and Tarita Thomas
Improvements in dosimetry with adaptive radiation therapy (ART) have been widely reported in the literature, in addition to the increased costs attributed to increased physician time and capital investment. ART utilization has been steadily rising, now with multiple available treatment platforms, but there is no generally accepted guideline for proper billing and reimbursement. No specific billing code for ART is currently available. Considering the heterogeneity of billing practices and limited published data on utilization trends, the ACRO Government Relations and Economics Committee developed a survey to understand current clinical and billing practices while gauging the opinions of the community about appropriate reimbursement.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Miami-Dade County Medical Association and the American College of Radiation Oncology. The Miami-Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians.
The Miami-Dade County Medical Association designates this activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
None of the planners or faculty of this activity had any financial relationships to disclose except for Paul Wallner who was an employee for Genesiscare USA (relationship has ended), a consultant for Health Management Associates, and an advisory board member for Nanocan Therapeutices, Inc. and Christopher Jahraus who is a consultant for RADformation, has other financial/material support from Klarity (Expert Witness) (relationship has ended), is a stock owner/investor in the privately held company Fuse Oncology, and was an advisory board member with Elekta (relationship has ended).
All of the financial relationships identified for these planners and faculty have been mitigated.
Print Page
ORIGINAL ARTICLE
next to the name of each of your CME credits.